中慧生物-B(02627)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02627 中慧生物-B

停牌 10-06 09:20:25

29.320

+0.000

0.00%

最高29.320	最低29.320	成交量0.00
今开29.320	昨收29.320	日振幅0.00%
总市值115.23亿	流通市值86.89亿	总股本3.93亿
成交额0.00	换手率0.00%	流通股本2.96亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02627","market":"HK","secType":"STK","nameCN":"中慧生物-B","latestPrice":29.32,"timestamp":1791249625972,"preClose":29.32,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":296361845,"shares":393000000,"eps":-0.8415440913264586,"marketStatus":"停牌","change":0,"latestTime":"10-06 09:20:25","open":29.32,"high":29.32,"low":29.32,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.7318742053962424,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791336600000},"marketStatusCode":5,"adr":0,"listingDate":1754841600000,"exchange":"SEHK","adjPreClose":29.32,"openAndCloseTimeList":[[1791250200000,1791259200000],[1791262800000,1791273600000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02627","defaultTab":"news","newsList":[{"id":"1188903437","title":"中慧生物-B发布9月股份变动月报，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1188903437","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188903437?lang=zh_cn&edition=full","pubTime":"2026-10-02 17:31","pubTimestamp":1790933471,"startTime":"0","endTime":"0","summary":"江苏中慧元通生物科技股份有限公司于2026年10月2日披露截至2026年9月30日的证券变动月报表。本报告期内，公司注册股本结构未发生变化，H股数量为296,361,845股，内资股数量为97,080,755股，对应法定注册股本分别维持人民币296,361,845元及人民币97,080,755元，两类股份在报告期内的数量和金额均与上月底持平。公司本月底法定注册股本总额仍为人民币393,442,600元。截至2026年9月30日，公司已发行股份及总股本维持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113505612","title":"中慧生物-B(02627)披露复牌进展：内控及法证调查持续推进 H股继续暂停交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1113505612","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113505612?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:56","pubTimestamp":1790762169,"startTime":"0","endTime":"0","summary":"中慧生物-B9月30日公告称，按香港联交所上市规则第13.09条及第13.24A条要求，公司发布复牌进展季度更新，并维持股份暂停交易状态。以下为公告要点：。目前调查已启动并在进行中，主要发现及结果将择时披露。自2026年4月1日09:00起，公司H股已在联交所暂停买卖，暂停状态仍将持续，直至另行通知。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191400371","title":"中慧生物-B（02627）披露新一届董事会及专门委员会成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1191400371","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191400371?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:42","pubTimestamp":1790167342,"startTime":"0","endTime":"0","summary":"2026年9月23日，江蘇中慧元通生物科技股份有限公司发布公告，公布公司董事会成员及其在四个专门委员会中的任职情况。现将公告核心信息整理如下：。上述安排自公告披露之日起生效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193632734","title":"中慧生物-B（02627）高层人事大调整：首席财务官更迭并提名两名执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1193632734","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193632734?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:35","pubTimestamp":1790166933,"startTime":"0","endTime":"0","summary":"江蘇中慧元通生物科技股份有限公司9月23日公告披露，董事会自当日起进行多项人事及组织架构调整，并继续维持股份停牌状态。以下为主要内容：。李润香自2026年9月23日起辞任公司执行董事及首席财务官职务。李润香确认与董事会无意见分歧，亦无需特别提请股东及香港联合交易所有限公司关注的其他事项。李润香辞任后不再担任上市规则第3.05条授权代表，许剑自2026年9月23日起接任。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669485268","title":"中慧生物-B(02627)：陈则及吴菁芸获提名为执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2669485268","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669485268?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:35","pubTimestamp":1790166903,"startTime":"0","endTime":"0","summary":"自2026年9月23日起，李女士已不再担任薪酬与考核委员会成员及董事会提名委员会成员，何一鸣先生已获委任为薪酬与考核委员会成员，而雷美嘉女士已获委任为提名委员会成员。李女士于辞任执行董事后已不再担任公司根据上市规则第3.05条所委任的授权代表，而许先生已获委任接替李女士担任授权代表，两者均自2026年9月23日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中慧生物-B(02627)：陈则及吴菁芸获提名为执行董事候选人","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120589295","title":"中慧生物-B8月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1120589295","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120589295?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:58","pubTimestamp":1788512303,"startTime":"0","endTime":"0","summary":"江蘇中慧元通生物科技股份有限公司于2026年9月4日披露的月报显示，截至2026年8月31日，公司的股本结构保持不变。H股数量为296,361,845股，面值人民币1元，注册股本296,361,845元；内资股数量为97,080,755股，面值同为人民币1元，注册股本97,080,755元。两类股份均较上月底无增减变化，合计注册股本仍为人民币393,442,600元。报告期内未发生新增发行、购回、注销或库藏股变化。截至8月末，公司股本总数始终保持稳定。本次报告由执行董事李潤香签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102744806","title":"中慧生物-B（02627.HK）再度延迟披露2025年年报及2026年中报 H股维持停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=1102744806","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102744806?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:35","pubTimestamp":1788176153,"startTime":"0","endTime":"0","summary":"江苏中慧元通生物科技股份有限公司8月31日晚间公告称：。按香港联交所上市规则，公司应在2026年8月31日或之前披露截至2026年6月30日止六个月的中期业绩，并在2026年9月30日或之前寄发中期报告。用以审议及批准2025年年度业绩及2026年中期业绩的董事会会议将继续顺延，召开日期目前尚未确定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118976213","title":"中慧生物-B7月股份变动月报表：股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1118976213","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118976213?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:58","pubTimestamp":1785833886,"startTime":"0","endTime":"0","summary":"中慧生物-B于2026年8月4日披露2026年7月股份变动月报表，披露期间为截至2026年7月31日。公告显示，公司本月注册股本及已发行股本均未发生变动，股本规模整体保持稳定。公司法定/注册股本方面，H股和内资股分别维持在296,361,845股与97,080,755股，面值均为人民币1元，合计393,442,600股，较上月无变化。截止7月底，公司已发行H股和内资股数量分别为296,361,845股及97,080,755股，均未出现新增发行、回购或注销等行为。本次公告由执行董事李润香签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131622956","title":"中慧生物-B6月股份变动月报表：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1131622956","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131622956?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:50","pubTimestamp":1783327830,"startTime":"0","endTime":"0","summary":"2026年7月6日，江苏中慧元通生物科技股份有限公司发布了截至2026年6月30日的股份变动月报表。报告期内，公司股本结构保持稳定，未发生新增发行、购回、注销或库藏股等变动。报告显示，当月没有新增股份发行、购回或注销活动，公司股本规模与上月底相比无变化。此外，当月并无股票期权或股权激励计划的授出、行使或失效记录。公司同时在公告中确认已遵守香港联合交易所有限公司上市规则及相关法律规定。公告由执行董事李润香签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645887094","title":"中慧生物-B(02627)：mRNA猴痘疫苗获中国药审中心的IND申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2645887094","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645887094?lang=zh_cn&edition=full","pubTime":"2026-06-23 18:10","pubTimestamp":1782209455,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B 发布公告，继本集团获美国食品药物监督管理局批准其于美国提交的临床研究用新药申请后，国家药品监督管理局药品审评中心已于2026年6月21日批准本集团自主研发的mRNA猴痘疫苗候选产品的IND申请。猴痘由猴痘病毒引发，而猴痘病毒是痘病毒科正痘病毒属的一员。其为全球首个同时获FDA及中国药审中心批准IND申请的mRNA猴痘疫苗候选产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02627","IND","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103756063","title":"中慧生物-B发布5月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1103756063","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103756063?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:12","pubTimestamp":1780564331,"startTime":"0","endTime":"0","summary":"江蘇中慧元通生物科技股份有限公司于2026年6月4日披露截至2026年5月31日的股份变动月报表。报告显示，公司于5月期间未出现新增发行、股权回购或注销，整体股本结构保持不变。其中，香港联交所上市的H股股份为296,361,845股，无新增或减持，期末保持与上月相同。公司确认，其已满足根据香港联交所上市规则所规定的公众持股量要求，并遵守所有适用的上市法规与相关法律规定。本次月报表由公司执行董事李润香女士签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638973502","title":"中慧生物-B(02627)委任雷美嘉为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2638973502","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638973502?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:31","pubTimestamp":1779881462,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B(02627)公布，雷美嘉女士已获选为第二届董事会独立非执行董事及董事会审计委员会成员，自2026年5月27日起生效。此外，柏淳已获委任为公司新任核数师，任期自2026年5月27日临时股东会结束起，直至公司下届股东周年大会结束为止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635787832","title":"中慧生物-B(02627)启动重组呼吸道合胞病毒疫苗(CHO细胞)(佐剂)的I期及II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2635787832","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635787832?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:44","pubTimestamp":1778676291,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B 发布公告，集团近期已启动集团自主研发的重组呼吸道合胞病毒疫苗(佐剂)的I期及II期临床试验。公司已于2025年8月就重组呼吸道合胞病毒疫苗(佐剂)取得中国国家药品监督管理局的新药临床试验批准。严重病例可危及生命。集团的重组呼吸道合胞病毒疫苗(佐剂)利用CHO细胞研制而成，可表达经修饰的pre-F蛋白。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","159646","02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459715","title":"中慧生物-B(02627)：中国药审中心批准MRNA RSV疫苗IND申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459715","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633459715?lang=zh_cn&edition=full","pubTime":"2026-05-08 20:57","pubTimestamp":1778245029,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B 发布公告，继集团于2025年11月7日获美利坚合众国食品药品监督管理局批准其于美国提交的新药临床试验申请后，国家药品监督管理局药品审评中心已批准集团自主研发的mRNA RSV疫苗候选产品的IND申请。目前在中国，RSV感染的治疗仍依赖广谱抗病毒药物及对症治疗。因此，迫切需要开发一种有效的RSV疫苗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","MRNA","BK4548","159646","BK4501","MRNY","BK4551","BK4585","BK4139","BK4532","02627","BK4534","BK4568","BK4533","MRNX","BK4588","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104412622","title":"国家药监局受理中慧生物-B mRNA呼吸道合胞病毒疫苗临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1104412622","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104412622?lang=zh_cn&edition=full","pubTime":"2026-05-08 20:56","pubTimestamp":1778244973,"startTime":"0","endTime":"0","summary":"中慧生物-B宣布，其针对呼吸道合胞病毒的mRNA疫苗候选药物的临床试验申请，已获得中国国家药品监督管理局药品审评中心的正式受理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144934479","title":"中慧生物-B更新2026年4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1144934479","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144934479?lang=zh_cn&edition=full","pubTime":"2026-05-04 18:42","pubTimestamp":1777891334,"startTime":"0","endTime":"0","summary":"江苏中慧元通生物科技股份有限公司于2026年5月4日发布截至2026年4月30日的股份变动月报表。根据公告，本月公司整体股本结构维持不变。公告显示，截至2026年4月30日，公司法定注册股本包括普通股H股和内资股两类：H股注册股本296,361,845股、内资股注册股本97,080,755股，各股面值均为每股人民币1元。H股于本月底仍为296,361,845股，内资股为97,080,755股，无库藏股记录，总发行股本维持在393,442,600股。本次月报由执行董事李润香代表公司签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631591402","title":"中慧生物-B(02627)接获联交所复牌指引 继续停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2631591402","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631591402?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:03","pubTimestamp":1777457003,"startTime":"0","endTime":"0","summary":"倘本公司未能于2027年9月30日前补救导致其暂停买卖的事宜、达成复牌指引及获联交所信纳已全面遵守上市规则，并恢复股份买卖，上市科将建议上市委员会着手取消本公司的上市地位。根据上市规则第6.01及6.10条，联交所亦有权于适当情况下施加较短的特定补救期或立即取消本公司的上市地位。公司股份继续停牌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630733758","title":"中慧生物-B委任柏淳为新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2630733758","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630733758?lang=zh_cn&edition=full","pubTime":"2026-04-27 08:26","pubTimestamp":1777249560,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　中慧生物-B（02627）发布公告，鉴于德勤•关黄陈方会计师行（德勤）辞任后本公司核数师职位出缺，董事会已决议，在审计委员会推荐下，委任柏淳会计师事务所有限公司（柏淳）为本公司新核数师，自股东于本公司股东会上批准当日起生效，任期直至本公司下届周年股东会结束为止（建议委任核数师）。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-04-27/doc-inhvwwmp2494264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629840084","title":"中慧生物-B(02627)提名雷美嘉为独立非执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2629840084","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2629840084?lang=zh_cn&edition=full","pubTime":"2026-04-24 22:34","pubTimestamp":1777041244,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B(02627)发布公告，集团董事会建议提名雷美嘉女士为第二届董事会独立非执行董事候选人;委任雷女士为董事会审计委员会成员。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629840471","title":"中慧生物-B(02627)委任柏淳为新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2629840471","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2629840471?lang=zh_cn&edition=full","pubTime":"2026-04-24 22:29","pubTimestamp":1777040952,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B(02627)发布公告，鉴于德勤•关黄陈方会计师行(德勤)辞任后本公司核数师职位出缺，董事会已决议，在审计委员会推荐下，委任柏淳会计师事务所有限公司(柏淳)为本公司新核数师，自股东于本公司股东会上批准当日起生效，任期直至本公司下届周年股东会结束为止(建议委任核数师)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":-0.3876},{"period":"ytd","weight":-0.2714}],"compareEarnings":[{"period":"1week","weight":-0.0244},{"period":"1month","weight":-0.0628},{"period":"3month","weight":0.0231},{"period":"6month","weight":-0.0716},{"period":"1year","weight":-0.1142},{"period":"ytd","weight":-0.062}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏中慧元通生物科技股份有限公司是一家主要从事疫苗的研发、制造及商业化中国公司。该公司的产品管线包括两种核心产品，即四价流感病毒亚单位疫苗及在研冻干人用狂犬病疫苗，以及其他11种在研疫苗。该公司主要在中国市场开展业务。","exchange":"SEHK","name":"中慧生物-B","nameEN":"AB&B BIO-TECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中慧生物-B(02627)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中慧生物-B(02627)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中慧生物-B,02627,中慧生物-B股票,中慧生物-B股票老虎,中慧生物-B股票老虎国际,中慧生物-B行情,中慧生物-B股票行情,中慧生物-B股价,中慧生物-B股市,中慧生物-B股票价格,中慧生物-B股票交易,中慧生物-B股票购买,中慧生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中慧生物-B(02627)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中慧生物-B(02627)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}